Articles

KarXT (xanomeline-trospium) is currently in development to treat schizophrenia and psychosis related to Alzheimer disease. 

FDA Accepts New Drug Application for Karuna Therapeutics' Novel Schizophrenia Drug

Vivos becomes the first company to bring to market an alternative to continuous positive airway pressure (CPAP) or surgical neurostimulation implants for patients with severe OSA.

Vivos Therapeutics' Obstructive Sleep Apnea Oral Appliance Gains FDA 510(k) Clearance 

The CDC’s Morbidity and Mortality Weekly Report show pediatric influenza hospitalization rates returned to levels that preceded the COVID-19 pandemic.

'High Severity' Flu Season Among Children Spotlights Importance of Vaccination

The FDA will investigate all currently approved CAR T-cell treatments, as well as BCMA-directed and CD19-directed genetically modified autologous CAR T-cell therapies, for the risk of secondary T-cell malignancies.

FDA Investigating Risk of Secondary Cancers in Patients Administered CAR T-Cell Therapy

Mike Hollan is an assistant managing editor for 

 and can be reached at mhollan@mjhlifesciences.com.

A Q&A with Leslie Orne, CEO of Trinity Life Sciences, who discusses the latest developments in the life sciences industry and potential paths forward for companies in the space.

CEO of Trinity Life Sciences Discusses Healthcare Trends and How Companies Are Responding

Law aims to mitigate ongoing global drug shortages. 

Citing Ongoing Drug Shortages, Biden Administration Invokes Defense Production Act

Researchers highlight steps to be taken in the European Union to manage the challenge of ongoing drug shortages.

The Impact of Drug Shortages Outside of the United States

The launch of the Elecsys HBeAg quant immunoassay adds to Roche's viral hepatitis testing portfolio.

Roche Announces Launch of New Tool to Improve Hepatitis B Detection

Ogsiveo is the first and only drug approved by the FDA to treat desmoid tumors.

FDA Approves Ogsiveo to Treat Desmoid Tumors

For manufacturers who participate in the 340B program, costs have increased because they are required to provide steep discounts on their drugs at levels far below private market prices.

News